Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
NCT ID: NCT00278889
Last Updated: 2012-10-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
215 participants
INTERVENTIONAL
2006-01-31
2009-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Bevacizumab + FOLFOX
5-fluorouracil
intravenous infusion
Leucovorin
intravenous infusion
Oxaliplatin
intravenous infusion
Bevacizumab
intravenous infusion
2
AZD2171 + FOLFOX
AZD2171
oral tablet
5-fluorouracil
intravenous infusion
Leucovorin
intravenous infusion
Oxaliplatin
intravenous infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
AZD2171
oral tablet
5-fluorouracil
intravenous infusion
Leucovorin
intravenous infusion
Oxaliplatin
intravenous infusion
Bevacizumab
intravenous infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received prior systemic therapy for cancer,
* Cancer must have progressed during or after first treatment
Exclusion Criteria
* Poorly controlled hypertension
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jane Robertson
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Innsbruck, , Austria
Research Site
Vienna, , Austria
Research Site
Wels, , Austria
Research Site
Bonheiden, , Belgium
Ressearch Site
Brussels, , Belgium
Research Site
Edegem, , Belgium
Research Site
Ghent, , Belgium
Research Site
Leuven, , Belgium
Research Site
Winnipeg, Manitoba, Canada
Research Site
Moncton, New Brunswick, Canada
Research Site
Greater Sudbury, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Chomutov, , Czechia
Research Site
Nová Ves pod Pleší, , Czechia
Research Site
Pardubice, , Czechia
Research Site
Prague, , Czechia
Research Site
Montpellier, , France
Research Site
Saint-Herblain, , France
Research Site
Berlin, , Germany
Research Site
Freiburg im Breisgau, , Germany
Research Site
Halle, , Germany
Research Site
Hanover, , Germany
Research Site
Heidelberg, , Germany
Research Site
München, , Germany
Research Site
Stuttgart, , Germany
Research Site
Genova, , Italy
Research Site
La Torretta, , Italy
Research Site
Milan, , Italy
Research Site
Napoli, , Italy
Research Site
Rozzano, , Italy
Research Site
A Coruña, , Spain
Research Site
Barcelona, , Spain
Research Site
Madrid, , Spain
Research Site
Valencia, , Spain
Research Site
Zaragoza, , Spain
Research Site
Glasgow, , United Kingdom
Research Site
Ipswich, , United Kingdom
Research Site
Maidstone, , United Kingdom
Research Site
Newcastle upon Tyne, , United Kingdom
Research Site
Sutton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EUDRACT number 2005-003443-31
Identifier Type: -
Identifier Source: secondary_id
HORIZON I
Identifier Type: -
Identifier Source: secondary_id
D8480C00041
Identifier Type: -
Identifier Source: org_study_id